Keith A. Goldan - Jun 13, 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role: Chief Financial Officer
Signature: /s/ Michael A. Metzger, Attorney-in-Fact
Stock symbol: SNDX
Transactions as of: Jun 13, 2022
Transactions value $: $3,588,000
Form type: 4
Date filed: 6/15/2022, 04:12 PM
Previous filing: Mar 17, 2022
Next filing: Feb 3, 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SNDX	Common Stock	Award	$0	+3.21K		$0.00	3.21K	Jun 13, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SNDX	Stock Options (Right to buy)	Award	$3.59M	+230K		$15.60	230K	Jun 13, 2022	Common Stock	230K	$15.60	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Award of Restricted Stock Units that vest 50% of the shares on June 13, 2023 and the remaining 50% of the shares on June 13, 2024.
F2	Twenty five percent (25%) of the total number of shares underlying the option shall vest on June 13, 2023, and one-thirty-sixth (1/36th) of the remaining shares underlying the option shall vest monthly thereafter on the last day of each month, subject to the reporting person's continuous service on the relevant vesting dates.